Question 1

What are the potential side effects of Istodax?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma clinical trial (NCT03742921). Contact the study team or your healthcare provider for specific answers.

Question 2

How does Istodax compare to other treatments I might consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma clinical trial (NCT03742921). Contact the study team or your healthcare provider for specific answers.

Question 3

What should I expect during treatment with Istodax?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma clinical trial (NCT03742921). Contact the study team or your healthcare provider for specific answers.

Question 4

How will my progress be monitored during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma clinical trial (NCT03742921). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any specific eligibility criteria I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma clinical trial (NCT03742921). Contact the study team or your healthcare provider for specific answers.

What this study is about